Allergy Autoimmune Disease Diagnostics Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

The market comprises diagnostic tools, assays, reagents, and instruments designed to identify specific allergens and autoimmune antibodies. It serves a critical role in enabling early detection and personalized treatment strategies for patients. Key diagnostic modalities include immunoassay analyzers, enzyme-linked immunosorbent assays (ELISA), and complete blood count (CBC) testing equipment.

• •Combined allergy and autoimmune diagnostics segment valued at approximately USD 6.42 billion in 2025.
• •Key diagnostic technologies include immunoassay systems, ELISA kits, and rapid testing devices.
• •Primary end users are hospitals, diagnostic laboratories, and academic research institutes.

The increasing prevalence of allergic and autoimmune conditions worldwide is a primary catalyst, driven by environmental changes, pollution, and genetic factors. An aging global population further contributes to higher diagnosis rates of autoimmune disorders. Advancements in biotechnology, particularly in biomarker discovery and molecular diagnostics, are enabling more accurate and efficient testing.

• •Rising incidence of allergies and autoimmune disorders globally, linked to urbanization and environmental factors.
• •Growing public and clinical awareness leading to increased screening and earlier diagnosis.
• •Technological innovations, such as multiplex assays and advanced immunoassays, improving test accuracy and turnaround times.

The market is segmented by product into assays, kits, reagents, and instruments. By test type, it includes specific allergen tests, autoantibody tests (such as ANA, CRP, and Rheumatoid Factor), and routine blood tests. Geographically, North America currently holds the largest market share due to advanced healthcare infrastructure and high disease prevalence, while the Asia-Pacific region is anticipated to witness the fastest growth rate.

• •By product: assays, reagents, kits, and diagnostic instruments are the main categories.
• •By disease type: segmentation includes systemic autoimmune diseases and localized conditions.
• •Regional dominance: North America leads, with Asia-Pacific emerging as the fastest-growing region.

What are the recent trends and outlook?

The market is moving towards more personalized and integrated diagnostic solutions, incorporating artificial intelligence and data analytics. Point-of-care testing and at-home allergy testing kits are gaining traction, driven by consumer demand for convenience. The ongoing development of multiplex assays that can test for multiple allergens or biomarkers simultaneously is expected to shape future product offerings.

• •Growing integration of digital health platforms and AI for predictive allergy and autoimmune disease analytics.
• •Increased adoption of point-of-care (POC) diagnostics and direct-to-consumer testing models.
• •Development of multiplex assays enabling simultaneous screening for multiple conditions.